Daewoong Pharmaceutical and Ildong Pharmaceutical have made late entries in the market for diabetes treatment containing 'dapagliflozin.'

Although the door to the biosimilar market for dapagliflozin opened in April last year, these two companies did not join the market immediately. It was presumed because of the contract binding with AstraZeneca, which owns the original product.

After resolving the binding contract and with Forxiga’s imminent withdrawal from the Korean market, two companies have likely entered the competition for the market.

According to industry sources on July 3rd, Daewoong Pharmaceutical’s 'Forxilo Tab 10 mg (dapagliflozin propanediol hydrate)' and Il